摘要
目的探讨米诺环素辅助治疗精神分裂症阴性症状的效果及免疫学机制。方法将92例符合美国《精神疾病诊断与统计手册(第4版)》(DSM-IV)诊断标准、以阴性症状为主且单一利培酮治疗的精神分裂症患者随机分为米诺环素组(n=46)或安慰剂对照组(n=46),治疗周期为16周。于入组及出组时以阴性症状评定量表(SANS)、阳性和阴性症状量表(PANSS)评定疗效,测定治疗前后白介素1-β(IL-1β)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)浓度变化。结果 PANSS阴性症状评分和总评分与安慰剂组相比,减分差异有统计学意义(P<0.01);两组治疗前后除NO外其余两个因子的浓度变化均无统计学意义(P>0.05)。结论米诺环素辅助治疗精神分裂症的阴性症状有效,但作用机制仍不明,是否通过抑制NO浓度的变化尚需进一步的研究。
Objective Our study explore the efficacy and mechanism of minocycline combining with risperidone in the treatment of negative symptom in early-phase schizophrenia.Methods Ninety-two patients with early stage schizophrenia treated with risperidone were randomly assigned to receive minocycline or placebo.Two treatment group both take 1 6-weeks.The clinical effectand immune factor were assessed with the Scale for the Assessment of Negative Symptoms （SANS）,the Positive and Negative Syndrome Scale （PANSS）,concentration of IL-1β,TNF-α,NObefore the treatment and the end.Results Sub-jects receiving minocycline had greater improvements on PANSS negative subscale scores and PANSS total score （P〈0.01） when compared with those receiving placebo.Minocycline have no effect on the concentration of IL-1β,TNF-αexcept for NO.Conclusion The addition of minocycline to atypical antipsychoticdrugs in early schizophrenia had significant efficacy on neg-ative symptoms.The mechanism is still unknown and is speculated to be related to inhibited the concentration of NO.
出处
《四川精神卫生》
2014年第2期128-131,共4页
Sichuan Mental Health
基金
国家卫生部行业专项基金(201002003)
国家自然科学基金项目(81071093
30900485和81270019)
国家科技部科技重大专项"重大新药创制"(2012ZX09303014-001)
